
    
      A multinational, randomised, double-blind, placebo-controlled phase IIIb trial to evaluate
      the effect of ticagrelor twice daily on the incidence of cardiovascular death, myocardial
      infarction or stroke in patients with type 2 diabetes mellitus
    
  